to show additional ratios from the two by two tables shown there. Event numbers are from manuscript Table 2 . Comparisons are of lowest and highest months for 25OHD raw : 6 months vs 6, 4 vs 4 and 3 vs 3 (see Table 1 Explanation: Concern was expressed that the top 20 percent of 25OHD adj values, used for the baseline low-risk hazard ratio of 1.0 in these analyses, might nevertheless be heterogeneous, concealing increased risk at the very highest readings (as some investigators report) and the 20% should be split further to see if results were consistent.
Discussion: The top 5% have slightly lower risk than the top 10% (which includes them) and this is marginally lower than that for the top 20%. The top 2.5% do not show a further decline (or a significant increase) but we are dealing with relatively small numbers as high readings are uncommon. Age and sex composition of groups are sufficiently similar not to necessitate adjustments before making these comparisons.
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Methods

Study design 4 Present key elements of study design early in the paper
Abstract, Material and Methods section on Scottish Heart Health Extended Cohort. Missing data section of Discussion.
(e) Describe any sensitivity analyses
In Materials and Methods, Results, Discussion and in Web Supplement. Many participants refused or failed venepuncture (and sometimes serum specimens were scanty. Both the media, and unfortunately the police were against syringes and needles during a prevalent HIV scare, particularly in Edinburgh, so participants were nervous -thinking you could get it from sterile needles -as were some survey nurses).
Results
Participants
Some participants refused follow-up.
16 000 participants were considered to have sufficiently complete data in 2000 for their data to be extracted and transferred to the Helsinki Data Centre for the MORGAM collaboration (more concerned with DNA studies at first, in which SHHEC did not participate). Available serum was not a criterion at that time but it must have been available to provide baseline risk factor data originally. Serum was depleted in a series of case-control and quality control studies done between recruitment and 2007.
Later MORGAM Biomarker study was initiated.
14 751 serum specimens (and about 2800 plasma) were transferred to Mainz (later there are large number of reviews published) in view of need to explain at reasonable length the rationale, novel methods, and results in a study large enough to stand alone, until we hope it is replicated elsewhere, when results from similar studies can be discussed.
Generalisability 21
Discuss the generalisability (external validity) of the study results
Awaits replication, but important data from a northern latitude which should apply elsewhere.
Other information
Fundingapplicable, for the original study on which the present article is based 
